22nd Annual Update in Pulmonary Hypertension

This live CME/CNE accredited activity is the only New England symposium that illustrates novel pathways implicated in the pathogenesis of pulmonary vascular disorders and provides state of the art therapeutic approaches to the management of pulmonary hypertension. This education is accomplished via a combination of didactic lectures, case-based plenary and breakout discussions that feature leading experts as presenters and panelists. All presentations will be based on current evidence-based guidelines, research, and patient-centered outcomes.

Educational Outcome

This CE activity offers new and experienced healthcare providers state of the art education, recent data, case discussions, and practical guidance on the optimal screening and management of patients who have or are suspected of having pulmonary hypertension. It is expected that learners will utilize this education to make more informed treatment decisions that will measurably improve patient outcomes.

Objectives

After completing this activity, the participant should be better able to:

• Evaluate novel clinical trial designs and pathways being developed to improve treatment outcomes
• Examine clinical trial evidence on the safety and efficacy of current and emerging drug treatment options for PAH/PH, as well as clinical trials that have yielded negative results and what we can learn from them
• Review the pathogenesis, detection, and management challenges of methamphetamine-induced Pulmonary Hypertension
• Explain how to differentiate between the various PH Groups based on the WSPH Classification in the setting of comorbidities
• Debate the merits of aggressive up-front therapy vs. a more cautious approach
• Discuss the evolving treatment approaches to Groups 1-3 based on incorporation of the latest evidence
• Describe the clinical implications of pulmonary hypertension complicating parenchymal lung disease

Target Audience

This activity is intended for physicians (pulmonologists, cardiologists, rheumatologists and general practitioners), fellows, residents, nurse practitioners, registered nurses and other healthcare practitioners engaged in the care of patients with pulmonary arterial hypertension.